title: Treatment of peripheral T cell lymphoma with an intensive protocol ACEP (adriamycin, cyclophosphamide, etoposide and prednisolone) and ifosfamide showing an important response and overall survival rates.
abstract: Peripheral T Cell Lymphoma (PTCL) is a group of lymphoid malignancies which has never been treated with any confidence as opposed to its counterpart B Cell Lymphomas. Despite the studies, which were retrospective, the results in the majority of cases were disappointing, taking into consideration the aggressive clinical course of the disease, so survival did not exceed 2 years in median. To assess the response, progression-free survival and overall survival rates at 5 years using a new intensive combination chemotherapy. Enrolled patients were diagnosed with PTCL, confirmed by a referenced pathologist, treated with the new chemotherapy ACEP X 6 (Doxorubicine 75 mg/m² on day 1 + Cyclophosphamide 1,200 mg/m² on day 1 + Etoposide 300 mg/m² on day 1 and Prednisolone 60 mg/m² from day 1 through day 5) and Ifosfamide X 4 (Ifosfamide 4 grams/m² on day 1) which were given after the completion of the first 6 cycles of ACEP. The study was performed at Al-Bairouni University Hospital, and the study was approved by the Syrian Association of Clinical Oncology. Twenty-five patients underwent the treatment. Most of them showed a complete response after the completion of the first six cycles (17/25) forming 68 % of patients, while another 5 patients became complete responders after the completion of treatment. Consequently, 22 patients are still living after 5 years, with an overall survival rate of 88 %. (ACEP) and Ifosfamide appears to be a good choice in PTCLs, in light of the good response and overall survival rates, taking into account the acceptable toxicity profile. However, a larger sample is needed to make it an acceptable new combination chemotherapy for PTCLs patients.
authors.affiliation: Department of Hematology and Medical Oncology, Al Bairouni University Hospital, Damascus, Syria. maheroncology@yahoo.com
authors.forename: Maher
authors.initials: M
authors.lastname: Salamoon
authors.forename: Marouane
authors.initials: M
authors.lastname: Bachour
authors.forename: Taisir
authors.initials: T
authors.lastname: Hussein
authors.forename: Mazen
authors.initials: M
authors.lastname: Kenj
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D012189:Retrospective Studies; D015996:Survival Rate / Q000639:trends; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D007069:Ifosfamide
references.citation: Blood. 2006 Jan 1;107(1):265-76
references.pmid: 16150940
references.citation: J Clin Oncol. 1999 Apr;17(4):1244
references.pmid: 10561185
references.citation: Haematologica. 2005 Dec;90(12):1703-5
references.pmid: 16330450
references.citation: J Clin Oncol. 2004 Jul 15;22(14):2826-34
references.pmid: 15254050
references.citation: Blood. 1998 Jul 1;92(1):76-82
references.pmid: 9639502
references.citation: Ann Oncol. 2003 Dec;14(12):1768-75
references.pmid: 14630683
references.citation: Blood. 2004 Apr 1;103(7):2474-9
references.pmid: 14645001
references.citation: J Clin Oncol. 1988 Oct;6(10):1584-9
references.pmid: 3262720
references.citation: J Clin Oncol. 2006 Jun 1;24(16):2472-9
references.pmid: 16636342
references.citation: J Clin Oncol. 2004 Jun 1;22(11):2172-6
references.pmid: 15169805
references.citation: Ann Oncol. 2002 Jan;13(1):140-9
references.pmid: 11863096
references.citation: J Clin Oncol. 1997 Mar;15(3):1131-7
references.pmid: 9060555
references.citation: Ann Oncol. 1990;1(1):45-50
references.pmid: 1706610
references.citation: J Pathol. 2006 Oct;210(2):172-80
references.pmid: 16924587
references.citation: Cancer. 2005 May 15;103(10):2091-8
references.pmid: 15816054